Alprostadil

證據等級: L5

預測適應症: 10 個

Alprostadil: From Ductus-Dependent Congenital Heart Disease to Aortic Malformation

One-Sentence Summary

Alprostadil (prostaglandin E1, PGE1) is a naturally occurring prostaglandin used internationally as the standard of care for maintaining ductus arteriosus patency in neonates with ductus-dependent congenital heart disease, though it is not currently registered with the Therapeutic Goods Administration (TGA) in Australia. The TxGNN model predicts it may be effective for Aortic Malformation — encompassing interrupted aortic arch, critical coarctation of the aorta, and hypoplastic left heart syndrome — with 2 clinical trials and 20 publications supporting this direction. Notably, this prediction aligns with decades of established international clinical practice, making this a case where TxGNN confirms a globally recognised use that has yet to receive formal TGA registration in Australia.

Quick Overview

Item	Content
Original Indication	Not registered with TGA in Australia. Internationally established for maintenance of ductus arteriosus patency in ductus-dependent neonatal congenital heart disease; also registered elsewhere for peripheral arterial occlusive disease and erectile dysfunction.
Predicted New Indication	Aortic Malformation
TxGNN Prediction Score	99.98%
Evidence Level	L2
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Although formal mechanism of action data was not retrieved in this evidence pack, Alprostadil’s pharmacology is extensively documented in the peer-reviewed literature. Alprostadil is the synthetic form of prostaglandin E1, a naturally occurring eicosanoid. It binds to EP2 and EP4 prostanoid receptors on ductus arteriosus (DA) smooth muscle, elevating intracellular cyclic AMP (cAMP), which inhibits smooth muscle contraction and prevents spontaneous ductal closure. This mechanism was established in landmark studies by Olley et al. (Circulation, 1976) and Freed et al. (NEJM, 1981), and is now a cornerstone of neonatal cardiac critical care — incorporated into AHA, AAP, and ESC clinical guidelines.

Aortic malformations — particularly interrupted aortic arch (IAA), critical coarctation of the aorta, and hypoplastic left heart syndrome (HLHS) — are ductus-dependent lesions in which perfusion of the descending aorta and lower body depends entirely or substantially on blood flow through the ductus arteriosus. Without prostaglandin support, spontaneous ductal closure within the first hours to days of life causes abrupt haemodynamic collapse and death. Alprostadil infusion maintains ductal patency, allowing time for diagnosis, clinical stabilisation, transfer to a tertiary paediatric cardiac centre, and planned surgical correction (e.g., arch repair, Norwood procedure, or arterial switch). The 2015 review by Jonas (Semin Thorac Cardiovasc Surg, PMID 26686446) explicitly states that “the introduction of prostaglandin E1 in the late 1970s revolutionised the management of interrupted aortic arch.”

An important contextual point for Australian clinicians: the absence of large-scale Phase 3 RCTs for this indication does not reflect insufficient evidence — it reflects an ethical constraint. Withholding PGE1 from neonates with ductus-dependent aortic lesions in a controlled trial setting would be clinically unjustifiable. The evidence base is founded on decades of observational series, prospective case studies, one published RCT (PMID 19080093), and universal guideline endorsement. TxGNN’s 99.98% prediction score is consistent with this established clinical consensus. The primary barrier to formal use in Australia is the absence of TGA registration, not a lack of pharmacological rationale.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT04054115	Phase 1	Terminated	10	Direct evaluation of Alprostadil’s acute effects on cerebral and pulmonary blood flow following bidirectional cavopulmonary connection (BCPC/Glenn operation) in single-ventricle congenital heart disease. Alprostadil was demonstrated to increase cerebral blood flow by dilating the pulmonary vasculature. Terminated early (n=10), limiting statistical power, but provides direct pharmacodynamic safety and efficacy signals relevant to complex congenital aortic and cardiac malformations.
NCT02042092	N/A	Completed	39	Cross-sectional imaging study comparing colour Doppler ultrasonography (CDUS) versus MRI angiography in patients with systemic large vessel vasculitis affecting supraaortic vessels including the aorta. Not a drug intervention study; included as a disease population reference for aortic malformation imaging and assessment methodology. Relevance to Alprostadil pharmacotherapy is indirect.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19080093	2008	Prospective RCT	Zhonghua Yi Xue Za Zhi	Randomised controlled trial in 60 paediatric patients with congenital heart disease undergoing cardiopulmonary bypass; Alprostadil (Lipo-PGE1) combined with ulinastatin significantly reduced inflammatory cytokines (TNF-α, IL-8) and attenuated post-CPB lung injury compared to controls. Highest-tier evidence for Alprostadil’s protective role during congenital cardiac surgery.
6763200	1982	Prospective Case Series	Pharmacotherapy	Foundational evaluation of Alprostadil (PGE1) in neonates with ductus-dependent congenital malformations; demonstrated ductal dilation, improved pulmonary blood flow in right-sided obstructive lesions, and improved systemic perfusion in left-sided lesions including aortic arch abnormalities. Established the clinical basis for PGE1 in this indication.
26686446	2015	Review/Guideline	Semin Thorac Cardiovasc Surg	Comprehensive surgical management review of interrupted aortic arch; states that PGE1 introduction “revolutionised” IAA management and is the essential preoperative intervention before one-stage neonatal repair with direct arch anastomosis and VSD closure. Supports Alprostadil as cornerstone of preoperative stabilisation for aortic malformations.
7201134	1982	Prospective Case Series	Pediatr Cardiol	PGE1 infusion in 7 neonates with hypoplastic left ventricle and aortic atresia; 6 of 7 showed transient haemodynamic improvement following infusion. Illustrates the critical — though limited — role of PGE1 as a temporising bridge in extreme left-sided ductus-dependent aortic lesions.
32184038	2020	Retrospective Cohort	Asian J Surg	Contemporary institutional series of staged surgical repair for interrupted aortic arch; all patients received PGE1 infusion for preoperative haemodynamic stabilisation. Provides real-world evidence for routine Alprostadil use in aortic arch malformation management.
30347623	2019	Observational Cohort	J Neonatal Perinat Med	Prospective analysis of enteral feeding strategies in 51 neonates receiving PGE1 infusion for duct-dependent congenital lesions; reports low NEC incidence and supports cautious enteral feeding during Alprostadil infusion. Relevant to clinical management of neonates with aortic malformations awaiting surgery.
25647388	2014	Review	Cardiol Young	Preoperative management of critical aortic valvar stenosis in neonates; details PGE1 as essential for maintaining ductal patency and preventing left ventricular ischaemia prior to balloon valvuloplasty or surgical valvotomy. Applicable to the broader left-sided aortic lesion spectrum.
1926911	1991	Review	Ann Pharmacother	Practice guidance recommending PGE1 initiation at the birth hospital before neonatal transport when a ductus-dependent cardiac defect is suspected. Directly relevant to Australian retrieval medicine and the pre-transport stabilisation of neonates with undiagnosed aortic malformations.
28508920	2017	Case Report	Pediatr Cardiol	A neonate with critical aortic coarctation developed second- and third-degree atrioventricular block during prolonged low-dose PGE1 infusion; conduction disturbances resolved promptly upon discontinuation. Clinically important safety signal: cardiac rhythm monitoring is essential during extended Alprostadil infusion.
25263728	2014	Case Report	J Perinatol	Transient hypertrophic pyloric stenosis attributed to gastric mucosal proliferation from prolonged PGE1 infusion in a 35-week neonate with ductus-dependent congenital heart disease; resolved after cessation. Important adverse effect: gastrointestinal surveillance is warranted in neonates requiring extended Alprostadil infusion before surgical correction.

Australia Market Information

Alprostadil is not currently listed on the Australian Register of Therapeutic Goods (ARTG). There are no TGA-registered products containing Alprostadil available for commercial supply in Australia at the time of this report (data cutoff: 4 April 2026).

Access in Australia: Clinical use of Alprostadil in Australia requires access through the TGA Special Access Scheme (SAS — Category B for individual patients, or Category C for emergency use) or via an Authorised Prescriber arrangement. Clinicians should consult TGA guidance on unapproved therapeutic goods. For prescribing information, refer to the US FDA-approved product information for Prostin VR Pediatric® (alprostadil injection, Pfizer) or the EMA/MHRA-approved equivalent.

Safety Considerations

Formal safety data (TGA Product Information, approved warnings, and contraindications) is not available for Alprostadil in Australia as the drug is not TGA-registered. The following safety considerations are drawn from clinical literature included in this evidence pack and are relevant to neonatal use in aortic malformations:

Cardiac conduction abnormalities: Second- and third-degree atrioventricular block reported during prolonged low-dose PGE1 infusion, resolving on discontinuation (PMID 28508920). Continuous cardiac monitoring is essential.
Gastrointestinal complications: Transient hypertrophic pyloric stenosis (PMID 25263728) and antral foveolar hyperplasia (PMID 23521358) reported with prolonged infusion. Regular abdominal assessment recommended for neonates requiring extended Alprostadil courses.
Respiratory: Apnoea is a recognised dose-dependent adverse effect of PGE1 infusion; intubation equipment and respiratory support should be immediately available.
Systemic vasodilation: Hypotension, flushing, and pyrexia may occur; haemodynamic monitoring with arterial line access is standard practice.
Drug interactions: No DDI data was retrieved in this evidence pack. Refer to international product information for known interactions, particularly with other vasodilators and anticoagulants.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The use of Alprostadil in ductus-dependent aortic malformations is one of the most robustly established applications in neonatal cardiology, validated by over four decades of published evidence and incorporated into all major international paediatric cardiology and neonatology guidelines. The TxGNN model prediction at 99.98% is consistent with this established clinical consensus. The principal challenge for Australian practice is the absence of TGA registration — not a lack of pharmacological evidence — making access formalisation the primary actionable step.

To proceed, the following is needed:

TGA Access Pathway: Establish a formalised access pathway via TGA Special Access Scheme (SAS Category B) for individual patient access, or evaluate the feasibility of an Authorised Prescriber arrangement for neonatal/paediatric cardiac intensive care specialists
ARTG Registration Assessment: Assess the feasibility of a full TGA registration application for the ductus-dependent congenital heart disease indication, given the robust international evidence base and existing FDA/EMA approvals
Clinical Protocol Development: Engage with Australian paediatric cardiac centres (Royal Children’s Hospital Melbourne, Sydney Children’s Hospital Network, Queensland Children’s Hospital, Perth Children’s Hospital) to develop standardised monitoring protocols covering cardiac rhythm, respiratory function, haemodynamics, and gastrointestinal surveillance
Safety Documentation: Retrieve the complete DrugBank DB00770 mechanism of action data, contraindication profile, and drug interaction data to support prescriber information development
Retrieval Medicine Integration: Review protocols for neonatal transport services (e.g., Newborn Emergency Transport Service) to incorporate Alprostadil access for suspected ductus-dependent lesions in transit — consistent with international recommendations (PMID 1926911)

⚠️ This report is generated for research and clinical planning purposes only and does not constitute medical advice. Drug repurposing candidates require regulatory approval and clinical validation before therapeutic application. Data cutoff: 4 April 2026.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.